Adjuvants in micro‐ to nanoscale: current state and future direction

Gupta, Ankur; Schanen, Brian; Seal, Sudipta

doi:10.1002/wnan.1354

Cited by 12 publications

(14 citation statements)

References 126 publications

(325 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An antigen, once adsorbed or encapsulated by nanoparticles, may be used as an adjuvant for optimization of the immune response aer vaccination. [97][98][99][100][101][102] In 1986, Japanese researchers 103 rst reported success in generating antibodies against glutamate by using colloidal gold particles as a carrier. Subsequently, a number of papers were published whose authors applied and further developed this technique to obtain antibodies to the following haptens and complete antigens: amino acids; 104 142 In all these studies, the haptens or complete antigens were directly conjugated to colloidal gold particles, mixed with complete Freund's adjuvant or alum, and used for animal immunization.…”

Section: Production Of Antibodies By Using Gold Nanoparticlesmentioning

confidence: 99%

Immunological Properties of Gold Nanoparticles

Дыкман¹,

Khlebtsov²

2017

Gold Nanoparticles in Biomedical Applications

View full text Add to dashboard Cite

In the past decade, gold nanoparticles have attracted strong interest from the nanobiotechnological community owing to the significant progress made in robust and easy-to-make synthesis technologies, in surface functionalization, and in promising biomedical applications. These include bioimaging, gene diagnostics, analytical sensing, photothermal treatment of tumors, and targeted delivery of various biomolecular and chemical cargos. For the last-named application, gold nanoparticles should be properly fabricated to deliver the cargo into the targeted cells through effective endocytosis. In this review, we discuss recent progress in understanding the selective penetration of gold nanoparticles into immune cells. The interaction of gold nanoparticles with immune cell receptors is discussed. As distinct from other published reviews, we present a summary of the immunological properties of gold nanoparticles. This review also summarizes what is known about the application of gold nanoparticles as an antigen carrier and adjuvant in immunization for the preparation of antibodies in vivo. For each of the above topics, the basic principles, recent advances, and current challenges are discussed. Thus, this review presents a detailed analysis of data on interaction of gold nanoparticles with immune cells.Emphasis is placed on the systematization of data over production of antibodies by using gold nanoparticles and adjuvant properties of gold nanoparticles. Specifically, we start our discussion with current data on interaction of various gold nanoparticles with immune cells. The next section describes existing technologies to improve production of antibodies in vivo by using gold nanoparticles conjugated with specific ligands. Finally, we describe what is known about adjuvant properties of bare gold or functionalized nanoparticles. In the Conclusion section, we present a short summary of reported data and some challenges and perspectives.

show abstract

Section: Production Of Antibodies By Using Gold Nanoparticlesmentioning

confidence: 99%

Immunological Properties of Gold Nanoparticles

Дыкман¹,

Khlebtsov²

2017

Gold Nanoparticles in Biomedical Applications

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

“…Aluminium based adjuvants (ABA) are included in human vaccinations to boost or potentiate the immune response, to the injected antigen 1 . Whilst a consensus upon the immunomodulatory mechanism of action of ABA has yet to be reached, it has become increasingly recognised that activation of the innate immune response is crucial for increased antibody titres 1 2 . The continued and widespread use of ABA has followed the emergence of recombinantly expressed protein antigens of high purity as a safer alternative to inactivated or attenuated pathogens 2 3 .…”

mentioning

confidence: 99%

Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations

Mold

Shardlow

Exley

2016

Sci Rep

View full text Add to dashboard Cite

Aluminium adjuvants remain the most widely used and effective adjuvants in vaccination and immunotherapy. Herein, the particle size distribution (PSD) of aluminium oxyhydroxide and aluminium hydroxyphosphate adjuvants was elucidated in attempt to correlate these properties with the biological responses observed post vaccination. Heightened solubility and potentially the generation of Al3+ in the lysosomal environment were positively correlated with an increase in cell mortality in vitro, potentially generating a greater inflammatory response at the site of simulated injection. The cellular uptake of aluminium based adjuvants (ABAs) used in clinically approved vaccinations are compared to a commonly used experimental ABA, in an in vitro THP-1 cell model. Using lumogallion as a direct-fluorescent molecular probe for aluminium, complemented with transmission electron microscopy provides further insight into the morphology of internalised particulates, driven by the physicochemical variations of the ABAs investigated. We demonstrate that not all aluminium adjuvants are equal neither in terms of their physical properties nor their biological reactivity and potential toxicities both at the injection site and beyond. High loading of aluminium oxyhydroxide in the cytoplasm of THP-1 cells without immediate cytotoxicity might predispose this form of aluminium adjuvant to its subsequent transport throughout the body including access to the brain.

show abstract

“…Such adjuvant carriers can deposit antigens at the injection sites, enhance their presentation to immunocompetent cells, and induce the production of necessary cytokines. Particularly promising in this regard are various nanoscale particle carriers [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. Such nanocarriers can be used as adjuvants in the preparation of antibodies and nextgeneration vaccines.…”

Section: Introductionmentioning

confidence: 99%

Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases

Дыкман

2020

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Vaccination remains very effective in stimulating protective immune responses against infections. An important task in antibody and vaccine preparation is to choose an optimal carrier that will ensure a high immune response. Particularly promising in this regard are nanoscale particle carriers. An antigen that is adsorbed or encapsulated by nanoparticles can be used as an adjuvant to optimize the immune response during vaccination. a very popular antigen carrier used for immunization and vaccination is gold nanoparticles, with are being used to make new vaccines against viral, bacterial, and parasitic infections. Areas covered: This review summarizes what is currently known about the use of gold nanoparticles as an antigen carrier and adjuvant to prepare antibodies in vivo and design vaccines against viral, bacterial, and parasitic infections. The basic principles, recent advances, and current problems in the use of gold nanoparticles are discussed. Expert opinion: Gold nanoparticles can be used as adjuvants to increase the effectiveness of vaccines by stimulating antigen-presenting cells and ensuring controlled antigen release. Studying the characteristics of the immune response obtained from the use of gold nanoparticles as a carrier and an adjuvant will permit the particles' potential for vaccine design to be increased.

show abstract

Adjuvants in micro‐ to nanoscale: current state and future direction

Cited by 12 publications

References 126 publications

Immunological Properties of Gold Nanoparticles

Immunological Properties of Gold Nanoparticles

Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations

Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases

Contact Info

Product

Resources

About